GICS Sector : Healthcare
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Eyepoint's financial performance in Q3 2025 was marked by a significant decline in total net revenue, which came in at $1 million compared to $10.5 million in the same quarter last year. This decrease was primarily driven by the recognition of deferred revenue related to the company's 2023 agreement for the license of YUTIQ product rights in the prior year period. The company's EPS also came in at -$0.85, missing estimates of -$0.77. The cash and investments on September 30, 2025, totaled $204 million, a significant decrease from $371 million as of December 31, 2024.
Publication Date: Nov -26
The company's cash position was bolstered by a $172 million follow-on financing completed in October, which is expected to fund operations into Q4 2027, well beyond the expected top-line Phase III wet AMD data in 2026. This financing will enable the execution of the Phase III DME program, which consists of two non-inferiority trials, COMO and CAPRI, evaluating DURAVYU 2.7 milligrams versus on-label aflibercept control.
Eyepoint has made significant progress in its clinical programs, completing enrollment of the LUCIA trial, the second Phase III trial for DURAVYU in wet AMD, in July. Top-line data for DURAVYU and wet AMD is expected in mid-2026. The company is also moving forward with a pivotal Phase III DME program, with first patient dosing expected in Q1 2026. DURAVYU is the only tyrosine kinase inhibitor or TKI in development for DME, and its potential multi-MOA blocking VEGF, PDGF, and IL-6 signaling may be uniquely suited to effectively address multifactorial retinal diseases.
Analysts expect a significant decline in revenue growth next year, at -70.0%. The current valuation metrics, such as P/S Ratio of 23.89 and EV/EBITDA of -4.56, indicate that the market is pricing in significant growth expectations. However, the company's current financial performance and clinical progress will be crucial in determining whether these expectations are met.
Eyepoint's Q3 2025 earnings report highlights the company's continued focus on its clinical programs and pipeline development. While the financial performance was weak, the company's cash position and financing provide sufficient runway to execute on its clinical plans. As the company moves forward with its Phase III DME program and awaits top-line data for DURAVYU and wet AMD, investors will be closely watching for progress and potential catalysts for growth.
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Nov -19
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov -17
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript
Nov -05
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
Nov -05
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
Nov -05
EyePoint Announces Participation at Upcoming Investor Conferences
Nov -03
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
Oct -29
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct -16
EyePoint Pharmaceuticals' 9.27% growth in License and Collaboration Agreements is driven by increasing demand for ophthalmic treatments, strategic partnerships, and expansion into new markets. The company's innovative pipeline and strong intellectual property portfolio also contribute to its growth, as well as its ability to secure lucrative licensing deals with major pharmaceutical companies.
EyePoint Pharmaceuticals' 8.9% growth in Ophthalmic Products is driven by increasing demand for innovative treatments, expanding indications for existing products, and strategic partnerships. Growing prevalence of eye diseases, such as diabetic retinopathy and age-related macular degeneration, also contribute to the segment's growth.
Strong demand for EyePoint's ophthalmic products, particularly YUTIQ and DEXYCU, drives royalty growth. Increasing adoption in the U.S. and expansion into international markets contribute to the 8.9% growth. Additionally, the company's strategic partnerships and collaborations, such as with Ocumension Therapeutics, further boost revenue.
DEXYCU is a corticosteroid indicated for the treatment of postoperative inflammation and pain associated with ocular surgery.
YUTIQ is a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
ILUVIEN is a fluocinolone acetonide intravitreal implant indicated for the treatment of diabetic macular edema (DME) in patients who have an artificial lens implanted.
EyePoint Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for eye diseases.
EyePoint Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the presence of insurance companies.
EyePoint Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment.
EyePoint Pharmaceuticals, Inc. has a high threat of new entrants due to the growing demand for eye care treatments and the presence of venture capital funding for startups.
EyePoint Pharmaceuticals, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 2.01% |
| Debt Cost | 12.54% |
| Equity Weight | 97.99% |
| Equity Cost | 12.54% |
| WACC | 12.54% |
| Leverage | 2.05% |
Value: 6.0
Growth: 4.0
Quality: 3.9
Yield: 0.0
Momentum: 7.5
Volatility: 5.0
1-Year Total Return ->
Value: 5.0
Growth: 7.2
Quality: 5.1
Yield: 0.0
Momentum: 5.0
Volatility: 4.0
1-Year Total Return ->
Value: 6.2
Growth: 5.0
Quality: 4.3
Yield: 0.0
Momentum: 6.0
Volatility: 2.3
1-Year Total Return ->
Value: 4.2
Growth: 4.6
Quality: 4.1
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.6
Growth: 2.3
Quality: 4.9
Yield: 0.0
Momentum: 7.5
Volatility: 1.0
1-Year Total Return ->
Value: 8.2
Growth: 6.9
Quality: 3.0
Yield: 0.0
Momentum: 1.0
Volatility: 2.7
1-Year Total Return ->